PCSK9 inhibitors for anti-inflammation in atherosclerosis: protocol for a systematic review and meta-analysis of randomised controlled trials
出版年份 2022 全文链接
标题
PCSK9 inhibitors for anti-inflammation in atherosclerosis: protocol for a systematic review and meta-analysis of randomised controlled trials
作者
关键词
-
出版物
BMJ Open
Volume 12, Issue 11, Pages e062046
出版商
BMJ
发表日期
2022-11-25
DOI
10.1136/bmjopen-2022-062046
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Associations Among PCSK9 Levels, Atherosclerosis-Derived Extracellular Vesicles, and Their miRNA Content in Adults With Obesity
- (2022) Chiara Macchi et al. Frontiers in Cardiovascular Medicine
- A novel prothrombotic role of proprotein convertase subtilisin kexin 9: the generation of procoagulant extracellular vesicles by human mononuclear cells
- (2022) Valentina Scalise et al. MOLECULAR BIOLOGY REPORTS
- Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting
- (2021) Roberto Scicali et al. ACTA DIABETOLOGICA
- A placebo‐controlled proof‐of‐concept study of alirocumab on postprandial lipids and vascular elasticity in insulin‐treated patients with type 2 diabetes mellitus
- (2020) Benjamin Burggraaf et al. DIABETES OBESITY & METABOLISM
- Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1
- (2020) Ulf Landmesser et al. CARDIOVASCULAR RESEARCH
- Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis
- (2020) Robert P. Giugliano et al. STROKE
- Effect of PCSK-9 Inhibitors on Lipid-Rich Vulnerable Coronary Plaque Assessed by Near-Infrared Spectroscopy
- (2020) Hiroyuki Omori et al. JACC-Cardiovascular Imaging
- Adding Alirocumab to Rosuvastatin Helps Reduce the Vulnerability of Thin-Cap Fibroatheroma
- (2020) Yoichiro Sugizaki et al. JACC-Cardiovascular Imaging
- An Update on the Role of PCSK9 in Atherosclerosis
- (2020) Ece Yurtseven et al. Journal of Atherosclerosis and Thrombosis
- Immunity and Inflammation in Atherosclerosis
- (2019) Dennis Wolf et al. CIRCULATION RESEARCH
- Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease
- (2019) Sabina A. Murphy et al. JAMA Cardiology
- PCSK9 inhibition and inflammation: A narrative review
- (2019) Massimiliano Ruscica et al. ATHEROSCLEROSIS
- Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice
- (2019) Susanne Schuster et al. Scientific Reports
- PCSK9 Antibody Alirocumab Attenuates Arterial Wall Inflammation Without Changes in Circulating Inflammatory Markers
- (2019) Renate M. Hoogeveen et al. JACC-Cardiovascular Imaging
- Atherosclerosis
- (2019) Peter Libby et al. Nature Reviews Disease Primers
- Inflammatory and Cholesterol Risk in the FOURIER Trial
- (2018) Erin A. Bohula et al. CIRCULATION
- Pleiotropic Anti-atherosclerotic Effects of PCSK9 Inhibitors From Molecular Biology to Clinical Translation
- (2018) Angelos D. Karagiannis et al. Current Atherosclerosis Reports
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice
- (2017) Christine Landlinger et al. EUROPEAN HEART JOURNAL
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized Controlled Trials
- (2017) Aris Karatasakis et al. Journal of the American Heart Association
- PCSK9 signaling pathways and their potential importance in clinical practice
- (2017) Michał Wiciński et al. EPMA Journal
- Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms
- (2016) Amirhossein Sahebkar et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
- (2015) Brian Hutton et al. ANNALS OF INTERNAL MEDICINE
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- (2015) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
- (2015) L. Shamseer et al. BMJ-British Medical Journal
- Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
- (2015) L. Shamseer et al. BMJ-British Medical Journal
- Anti-inflammatory therapies for cardiovascular disease
- (2014) P. M. Ridker et al. EUROPEAN HEART JOURNAL
- Proprotein convertase subtilisin/kexin type 9 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cells
- (2010) Hong Lan et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
- (2008) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started